Driving your impact story and inspiring real change
Impact stories from our neurology journals
Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
Journal: Authors:
Journal of Neurology, Neurosurgery and Psychiatry Christina Zhukovsky, Sofia Sandgren, Thomas Silfverberg, Sigrun
Publication date: Einarsdottir, Andreas Tolf, Anne-Marie Landtblom, Lenka Novakova, Markus Axelsson, Clas Malmestrom, Honar Cherif, Kristina Carlson, Jan Lycke and Joachim Burman October 2020 This article has received 27 academic citations, and had 8 citations in Clinical Guidelines. See the full details below. Real world impact
Cited:
Top sources
in 8 Clinical Guideline documents from 3 countries with 4 different sources
Citation source Citations by source
Canada Germany The Netherlands Citing country Citing policy and guidance countries
Intergovernmental Organization (IGO)
BMJ Impact Analytics April 2024
Academic impact impa
Altmetric April 2024 and Dimensions April 2024
Let’s hear from Joachim Burman, Uppsala University Hospital, about this 2020 article published in Journal of Neurology, Neurosurgery and Psychiatry “ My research is particularly aimed at professionals working in low-income healthcare systems, so it is a necessity for it to be open access in order to reach them.”
Joachim Burman is a consultant neurologist at Uppsala University Hospital and an associate professor of neurology at the Department of Medical Sciences of Uppsala University. What inspired you to pursue research in this particular area? As a clinical neurologist with more than 20 years of experience, I have met many people with multiple sclerosis and disease onset in the pre- treatment era. Many of them are now severely disabled or have died from multiple sclerosis. They are a constant reminder that we must do better by offering healthcare and advanced treatments to more people. Over the years I came to realise that autologous hematopoietic stem cell transplantation could reverse disability in multiple sclerosis and induce prolonged remission in selected patients and that provided comfort to me as well as to my patients. How do you envision your research contributing to the broader field or addressing real-world issues? I have specialised in off-label treatments for MS, such as rituximab and autologous hematopoietic stem cell transplantation. These are cost- effective options that could be adopted in low-income countries as well. Since off-label treatment rarely gets support from pharmaceutical companies, it is nearly impossible to conduct randomised controlled trials, but with the right set-up, real-world studies can provide high-quality evidence as well.
Read full article
What motivated you to publish your work in an open access format? Open access is the best venue to reach a wider audience.
What do you see as the benefits of open access publishing compared to traditional publishing models? My research is particularly aimed at professionals working in low- income healthcare systems, so it is a necessity for it to be open access in order to reach them. What advice would you give to other researchers who are considering publishing their work in open access formats for the first time? I realise that many may not have the affordable means to publish with open access – but if you do, it is clearly worth it.
Read full article
The VITAL study and overall pooled analysis with the VIPS non-invasive stroke detection device
Journal:
Journal of NeuroInterventional Surgery
Authors:
Christopher P Kellner, Eric Sauvageau, Kenneth V Snyder, Kyle M Fargen, Adam S Arthur, Raymond D Turner and Andrei V Alexandrov
Publication Date:
March 2018
This article has received 68 academic citations, and garnered 5 citations in Clinical Guidelines. See the full details below. Real world impact
Cited:
in 5 Clinical Guideline documents from 2 countries with 2 different sources
Top sources
Citing policy and guidance countries
Citation source Citations by source
Australia
Citing country
Canad a
Canada UK
BMJ Impact Analytics April 2024
Intergovernmental Organization (IGO)
Academic impact imp
Altmetric April 2024 and Dimensions April 2024
Let’s hear from Christopher Kellner , Mount Sinai Hospital, about this 2018 article published in Journal of NeuroInterventional Surgery
“ I think [open access] is a great option to increase the reach and impact of [an] article.”
Christopher Kellner is an assistant professor at the Icahn School of Medicine at Mount Sinai. He is also a cerebrovascular neurosurgeon at Mount Sinai Hospital in New York, USA. How do you envision your research contributing to the broader field or addressing real-world issues? This study was one of the largest and earliest prospective studies to evaluate a novel portable stroke detection device. There have been many attempts since to evaluate the diagnostic accuracy of various technologies to achieve improved portable stroke diagnosis for early treatment and triage but thus far, no device has demonstrated adequate levels of accuracy. The space is still very much wide open. What do you see as the benefits of open access publishing compared to traditional publishing models? Open access makes something immediately accessible to the world and more sharable through social media. Non-open access articles, even when viewed by individuals who are part of an academic institution, remain behind a paywall and are not easily sharable. What advice would you give to other researchers who are considering publishing their work in open access formats for the first time?
I think it’s a great option to increase the reach and impact of the article.
Read full article
“ I think [open access] is a great option to increase the reach and impact of [an] article.” Dr. Christopher Kellner, Icahn School of Medicine at Mount Sinai, New York, USA “ My research is particularly aimed at professionals working in low-income healthcare systems, so it is a necessity for it to be open access in order to reach them.” Dr. Joachim Burman, Uppsala University Hospital, Sweden
Explore our range of journals in neurology
Start your publishing journey with us
Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8Powered by FlippingBook